Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings
Authors: Warren, R. B., Gooderham, M., Lain, E., Bissonnette, R., Huang, Y. H., Ringuet, J., Hoffmann, M., Pinter, A., Merola, J. F., Rubens, J. H., Fan, D., Hsu, M. C., Li, S., Yang, Y. W., DeKlotz, C. M. C., & Song, E. J. Read more on pubmed
Maintenance of Response With Icotrokinra, a Targeted Oral Peptide, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Randomized Treatment Withdrawal in Adults From the Phase 3, ICONIC-LEAD Study
Authors: Soung, J., Cui, Y., Bissonnette, R., Lebwohl, M. G., GonzĂĄlez-Cantero, Ă., Pinter, A., Rich, P., Prajapati, V. H., Miller-Kassamali, M., Cafone, J., Jiang, J., Li, S., Yang, Y. W., & Pink, A. E. Read more on pubmed
International Eczema Council Definitions of Low Disease Activity and Remission in Atopic Dermatitis: A Consensus Statement
Innovaderm/Indero founder Dr. Robert Bissonnette has coauthored the International Eczema Councilâs globally endorsed, expert-derived framework defining low disease activity and remission in atopic dermatitis, in JAMA Dermatology, April 2026. These standardized, clinically meaningful definitions provide a foundation for harmonized trial design, regulatory evaluation, and longitudinal comparative effectiveness research. Authors: Merola, J. F., Childs, B. A., Bartley, B. R., Bissonnette, R., Bieber, T., Guttman-Yassky, E., Paller, A. S., […]
Burden and Etiopathogenesis of Chronic Hand Eczema: A Complex Interplay of Genes, Environment, and Exposures
Authors: Molin, S., Yeung, J., & Bissonnette, R Different morphological and etiological subtypes of CHE appear to have overlapping and distinct features related to gene expression, proteomics, inflammatory biomarkers, and metagenomics, but data are limited and derived from small patient cohorts. The available evidence points to the broad activation of immune pathways implicated in JAK-STAT […]
The Gut Microbiome of Non-Atopic Chronic Hand Eczema (CHE) Subjects is Distinct and Enriched in Immuno-Modulatory Bacteria Species compared to Atopic-CHE and Healthy Subjects
Authors: Bissonnette R, Salem Y, Palijan A, Maari C, Proulx ES, Prifti DK, Hunter S, Routy B,Elkrief A. Read more on pubmed
Summary of Research: Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (DELTA 1 and DELTA 2): Results from Multicentre, Randomised, Controlled, Double-Blind, Phase 3 Trials
Authors: Bissonnette R, Albreiki F, Ehst BD, Al Hammadi A, Schliemann S, Yang B, Zhang J, BunickCG. Read more on pubmed
Dupilumab Treatment Up to 5 Years Shows No Clinically Meaningful Changes in Laboratory Parameters in Adults with Moderate-to-Severe Atopic Dermatitis
Authors: Simpson EL, Bissonnette R, Deleuran M, Nakahara T, Galus R, de Bruin-Weller M, Coleman A, van Spall M, Chen Z, Avetisova E, Bastian M, Khokhar FA. Read more on pubmed
Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasis
Authors: David Strawn, James G Krueger, Robert Bissonnette, Kilian Eyerich, Laura K Ferris, Amy S Paller, Andreas Pinter, Dylan Richards, Elizabeth Y Chen, Kate Paget, Daniel Horowitz, Roohid Parast, Joshua J Rusbuldt, Jocelyn Sendecki, Sunita Bhagat, Lynn P Tomsho, Ching-Heng Chou, Marta E Polak, Brice E Keyes, Emily Bozenhardt, Yuan Xiong, Wangda Zhou, Cynthia DeKlotz, […]
Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact Sites
Authors: Gooderham M, Lain E, Bissonnette R, Huang YH, Lynde CW, Hoffmann M, Song EJ, Weirich O, Ceitlin RHG, Rubens JH, Delozier AM, Ota T, Hsu M-C, Li S, DeKlotz CMC, Nunes F, Warren RB Read more on pubmed
Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials
Authors: Guttman-Yassky E, Kabashima K, Worm M, Luna PC, Hong CHH, Chovatiya R, Berstein JA, Kern JS, Ehst BD, Magnolo N, Herranz-Pinto P, Stein Gold L, Sofen H, Pink AE, Esfandiari E, Arai T, Shi R, Barragan C, Kricorian G, Schwartz-Sagi L, Bissonnette R Read more on pubmed
